Drugs & Therapy Perspectives

, Volume 34, Issue 10, pp 457–465 | Cite as

Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use

  • Katherine A. Lyseng-Williamson
Adis Drug Q&A


Oral cabozantinib tablets (Cabometyx®) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indication of cabozantinib tablets (i.e. treatment of advanced RCC following prior VEGF-targeted therapy) has been extended to include the first-line treatment of advanced RCC in treatment-naïve adults with intermediate or poor risk (EU) and all patients with advanced RCC (USA). These label extensions are based on the results of a randomized, open-label phase 2 trial, in which adults with metastatic RCC of poor or intermediate risk received targeted first-line treatment with cabozantinib or standard-of-care sunitinib. Relative to sunitinib, cabozantinib significantly prolonged median progression-free survival (primary endpoint; investigator and independent assessments), and increased the objective response rate (investigator assessment). The tolerability profile of cabozantinib is comparable to those of other tyrosine kinase inhibitors, with adverse events being manageable with medical intervention, dosage reductions, treatment interruption and/or permanent discontinuation.



The manuscript was reviewed by: E. Gallardo, Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació ParcTaulí I3P, Universitat Autònoma de Barcelona, Sabadell, Spain; B. Maughan, Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. During the peer review process, Ipsen Pharma (EU) and Exelixis, Inc. (USA), the marketing-authorization holders of cabozantinib, were also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with ethical standards


The preparation of this review was not supported by any external funding.

Conflicts of interest

K. A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.


  1. 1.
    National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): kidney cancer (version 4.2018). Fort Washington: National Comprehensive Cancer Network®, Inc.; 2018.Google Scholar
  2. 2.
    Garcia-Roig M, Ortiz N, Lokeshwar V. Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? Curr Urol Rep. 2014;15:375.CrossRefPubMedCentralGoogle Scholar
  3. 3.
    Tannir NM, Schwab G, Grunwald V. Cabozantinib: an active novel multikinase inhibitor in renal cell carcinoma. Curr Oncol Rep. 2017;19(2):14.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Yu SS, Quinn DI, Dorff TB. Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. Onco Targets Ther. 2016;9:5825–37.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Gill DM, Hahn AW, Hale P, et al. Overview of current and future first-line systemic therapy for metastatic clear cell renal cell carcinoma. Curr Treat Options Oncol. 2018;19(1):6.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Powles T, Albiges L, Staehler M, et al. Updated European Association of Urology Guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer. Eur Urol. 2018;73(3):311–5.CrossRefGoogle Scholar
  7. 7.
    Cabometyx® (cabozantinib) 20, 40 and 60 mg oral tablets: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
  8. 8.
    Cabometyx® (cabozantinib) 20, 40 and 60 mg tablets, for oral use: US prescribing Information. South San Francisco: Exelixis, Inc.; 2017.Google Scholar
  9. 9.
    Cometriq® (cabozantinib) 20 and 80 mg capsules: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
  10. 10.
    Cometriq® (cabozantinib) 20 and 80 mg capsules, for oral use: US prescribing Information. South San Francisco: Exelixis, Inc.; 2018.Google Scholar
  11. 11.
    Nguyen L, Benrimoh N, Xie Y, et al. Pharmacokinetics of cabozantinib tablet and capsule formulations in healthy adults. Anticancer Drugs. 2016;27(7):669–78.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–308.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Xie Z, Lee YH, Boeke M, et al. MET inhibition in clear cell renal cell carcinoma. J Cancer. 2016;7(10):1205–14.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lacy SA, Miles DR, Nguyen LT. Clinical pharmacokinetics and pharmacodynamics of cabozantinib. Clin Pharmacokinet. 2017;56(5):477–91.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Lacy S, Nielsen J, Yang B, et al. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2018;81(6):1061–70.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Nguyen L, Holland J, Ramies D, et al. Effect of renal and hepatic impairment on the pharmacokinetics of cabozantinib. J Clin Pharmacol. 2016;56(9):1130–40.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Lacy SA, Hsu B, Miles D, et al. Metabolism and disposition of cabozantinib in healthy male volunteers and pharmacologic characterization of its major metabolites. Drug Metab Dispos. 2015;43(8):1190–207.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Nguyen L, Holland J, Mamelok R, et al. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects. J Clin Pharmacol. 2015;55(11):1293–301.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–23.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–7 [erratum J Clin Oncol. 2017;35(32):3736].CrossRefPubMedCentralGoogle Scholar
  22. 22.
    Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–25.CrossRefPubMedCentralGoogle Scholar
  23. 23.
    Feldman DR, Feuilly M, Meng J, et al. ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203) [abstract no. e18690]. J Clin Oncol. 2018;36(Suppl).Google Scholar
  24. 24.
    Chen RC, Feuilly M, Meng J, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203) [abstract no. 4556]. J Clin Oncol. 2018;36(Suppl).CrossRefGoogle Scholar
  25. 25.
    Schmidt E, Lister J, Neumann M, et al. Cabozantinib versus standard-of-care comparators in the treatment of advanced/metastatic renal cell carcinoma in treatment-naive patients: a systematic review and network meta-analysis. Target Oncol. 2018;13(2):205–16.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Wallis CJD, Klaassen Z, Bhindi B, et al. First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analyses. Eur Urol. 2018. (Epub 2018).CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Schmidinger M, Danesi R. Management of adverse events associated with cabozantinib therapy in renal cell carcinoma. Oncologist. 2018;23(3):306–15.CrossRefPubMedCentralGoogle Scholar
  28. 28.
    George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial [abstract no. 582]. J Clin Oncol. 2018;36(Suppl 6S).Google Scholar
  29. 29.
    Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma: real-world data from an Italian managed access program. Clin Genitourin Cancer. 2018;16(4):e945–e951.CrossRefPubMedCentralGoogle Scholar
  30. 30.
    Ratta R, Verzoni E, Pantano F, et al. Effects of cabozantinib on bone turnover markers in patients with metastatic renal cell carcinoma [abstract no. 638]. J Clin Oncol. 2018;36(Suppl 6S).CrossRefGoogle Scholar
  31. 31.
    Miles DR, Lacy SA, Wada DR, et al. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes. Cancer Chemother Pharmacol. 2017;80(2):295–306.CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations